Oramed granted Australian patent for core technology
Marking a major milestone for the company, Oramed Pharmaceuticals, a developer of oral drug delivery systems, has received approval for a key patent by the Australian Patent Office. The patent covers an important part of Oramed's core technology, which allows for the oral delivery of peptides.
"Our patent position further strengthens Oramed and our competitive advantage in the development of an oral insulin capsule. The patent received will provide additional commercial protection for Oramed's technology and adds extended value to our existing IP-portfolio," said Nadav Kidron, CEO of Oramed.
Oramed's core product is an oral insulin capsule. The company's portfolio now consists of one issued patent and 34 patents pending for its technologies and products.